In vitro activity of A-192411.29, a novel antifungal lipopeptide

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 5, 2000, Pages 1242-1246

  Nilius, Angela M ^a   Raney, Patti M ^a   Hensey Rudloff, Dena M ^a   Wang, Weibo ^a   Li, Qun ^a   Flamm, Robert K ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 192411 29; AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; UNCLASSIFIED DRUG;

ARTICLE; ASPERGILLUS FUMIGATUS; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; FUNGICIDAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; MICROBIAL SENSITIVITY TESTS; PEPTIDES; PEPTIDES, CYCLIC;

EID: 0034058284     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.5.1242-1246.2000     Document Type: Article

References (20)

1. Bartizal, K., C. J. Gill, G. K. Abruzzo, A. M. Flattery, L. Kong, P. M. Scott, J. C. Smith, C. E. Leighton, A. Bouffard, J. F. Dropinski, and J. Balkovec. 1997. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41:2326-2332.
2. Fraser, R. S. 1993. Pulmonary aspergillosis: pathologic and pathogenic features. Pathol. Ann. 28:231-277.
3. Hood, S., and D. W. Denning. 1996. Treatment of fungal infections in AIDS. J. Antimicrob. Chemother. 37(Suppl. B):71-85.
4. Kurtz, M. B., and C. M. Douglas. 1997. Lipopeptide inhihitors of fungal glucan synthase. J. Med. Vet. Mycol. 35:79-86.
5. Kurtz, M. B., I. B. Heath, J. Marrinan, S. Dreikorn, J. Onishi, and C. Douglas. 1994. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase. Antimicrob. Agents Chemother. 38:1480-1489.
6. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
7. Pfaller, M. A., R. N. Jones, S. A. Messer, M. B. Edmond, and R. P. Wenzel. 1998. National surveillance of nosocomial blood stream isolates due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn. Microbiol. Infect. Dis. 31:327-332.
8. Pfaller, M. A., F. Marco, S. A. Messer, and R. N. Jones. 1998. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792) against clinical isolates of of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn. Microbiol. Infect. Dis. 30:251-255.
9. Pfaller, M, A., S. A. Messer, and S. Coffen. 1997. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents. Antimicrob. Agent Chemother. 41:763-766.
10. Pfaller, M. A., S. A. Messer, A. Houston, M. S. Rangel-Frausto, T. Wiblin, H. M. Blumberg, J. E. Edwards, W. Jarvis, M. A. Martin, H. C. Neu, L. Saiman, J. E. Patterson, J. C. Dibb, C. M. Roldan, M. G. Rinaldi, and R. P. Wenzel. 1998. National epidemiology of mycoses survey: a multicenter study of strain variation and antifungal susceptibility among isolates of Candida species. Diagn. Microbiol. Infect. Dis. 31:289-296.
11. Pfaller, M. A., S. A. Messer, Å. Karlsson, and A. Bolmström. 1998. Evaluation of the Etest method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media. J. Clin. Microbiol. 36:2586-2589.
12. Powderly, W. G. 1994. Resistant candidiasis. AIDS Res. Hum. Retrovir. 10:925-929.
13. Powderly, W. G., G. S. Kobayashi, G. P. Herzig, and G. Medoff. 1988. Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am. J. Med. 84:826-832.
14. Price, M. F., M. T. LaRocco, and L. O. Gentry. 1994. Fluconazole susceptibilities of Candida spp. and distribution of species recovered from blood cultures over a 5-year period. Antimicrob. Agents Chemotherap. 38:1422-1424.
15. Rex, J. H., C. R. Cooper, Jr., W. G. Merz, J. N. Galgiani, and E. J. Anaissie. 1995. Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob. Agents Chemother. 39:906-909.
16. Rex, J. H., M. A. Pfaller, M. G. Rinaldi, A. Polak, and J. N. Galgiani. 1993. Antifungal susceptibility testing. Clin. Microbiol. Rev. 6:367-381.
17. Tawara, S., F. Ikeda, K. Maki, Y. Morishita, K. Otomo, N. Teratani, T. Goto, M. Tomishima, H. Ohki, A. Yamada, K. Kawabata, H. Takasugi, K. Sakane, H. Tanaka, F. Matsumoto, and S. Kuwahara. 2000. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob. Agents Chemother. 44:57-62.
18. Vasquez, J. A., M. Lynch, D. Boikov, and J. D. Sobel. 1997. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob. Agents Chemother. 41:1612-1614.
19. Warnock, D. W. 1995. Fungal complications of transplantation: diagnosis, treatment, and prevention. J. Antimicrob. Chemother. 36(Suppl. B):73-90.
20. Zhanel, G. G., J. A. Karlowsky, G. A. J. Harding, T. V. Balko, S. A. Zelenitsky, M. Friesen, A. Kabani, M. Turik, and D. J. Hoban. 1997. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob. Agents Chemother. 41:863-865.